Short Interest in INVO Fertility, Inc (NASDAQ:IVF) Drops By 30.1%

INVO Fertility, Inc (NASDAQ:IVF) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totaling 66,048 shares, a drop of 30.1% from the December 15th total of 94,554 shares. Currently, 2.8% of the company’s stock are sold short. Based on an average daily trading volume, of 127,052 shares, the short-interest ratio is presently 0.5 days. Based on an average daily trading volume, of 127,052 shares, the short-interest ratio is presently 0.5 days. Currently, 2.8% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of INVO Fertility in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in INVO Fertility stock. Citadel Advisors LLC purchased a new position in INVO Fertility, Inc (NASDAQ:IVF) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned 1.19% of INVO Fertility at the end of the most recent reporting period. Institutional investors own 12.02% of the company’s stock.

INVO Fertility Stock Down 0.2%

IVF stock traded down $0.00 during trading on Friday, reaching $0.81. The stock had a trading volume of 46,289,934 shares, compared to its average volume of 127,060. The company’s 50 day moving average is $1.74 and its two-hundred day moving average is $7.50. The company has a market capitalization of $1.94 million, a price-to-earnings ratio of 0.00 and a beta of 2.60. INVO Fertility has a one year low of $0.71 and a one year high of $148.23.

About INVO Fertility

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.